MarketPulse
L

$LLY

175 articles found
110 positive
14 negative
50 neutral
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Can Eli Lilly Become First $2T Healthcare Giant? Three Growth Catalysts in Focus

Eli Lilly eyes $2 trillion valuation from weight-loss drugs, Alzheimer's breakthroughs, and AI-powered R&D following recent market pullback.
PFENVDALLYREGNhealthcare stocksweight loss drugs
Investing.comInvesting.com··Michael Kramer

Tech Giants Extend Market Lead as Oil Falls, Rates Decline

Tech stocks surge 12.5 points ahead of market amid falling oil, declining rates. AMD surges 18.61% on earnings; concentration risk raises correction concerns.
NVDAAMDMETAMSFTMU+7earnings resultsoptions market
BenzingaBenzinga··Vandana Singh

Novo Nordisk's Wegovy Pill Lifts Profit Outlook as GLP-1 Dominance Expands

Novo Nordisk's Q1 sales of $15.17B beat estimates, with Wegovy pill reaching 2M prescriptions. Company raised 2026 guidance to $42.39-$46.24B; shares surged 7.11%.
LLYNVOGLP-1 drugsQ1 earnings
BenzingaBenzinga··Vandana Singh

Eli Lilly's Omvoh Shows Durable Long-Term IBD Benefits, Bolstering Pipeline Confidence

Eli Lilly reports durable four-year efficacy data for Omvoh in IBD, with 63.5% ulcerative colitis remission and 92.4% Crohn's response rates, bolstering pipeline confidence.
LLYFDA approvalclinical trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Growth Trajectory Remains Compelling for Late Investors

Eli Lilly's 56% revenue growth and 156% EPS surge in Q1 2026, driven by GLP-1 dominance and oral formulation expansion, signal continuing upside potential for investors.
LLYearnings growthpharmaceutical growth
The Motley FoolThe Motley Fool··David Jagielski, Cpa

Eli Lilly Eyes $1,000 as GLP-1 Boom Lifts Stock 26% Higher

Eli Lilly stock near $960 has 26% upside to $1,215 consensus target, driven by blockbuster GLP-1 drugs Mounjaro and Zepbound delivering 60% revenue growth.
LLYvaluationrevenue growth
BenzingaBenzinga··Prnewswire

Eli Lilly Declares $1.73 Q2 2026 Dividend, Signaling Confidence in Pipeline

Eli Lilly declares $1.73 per-share Q2 2026 dividend payable June 10, reflecting strong financial footing and cash generation capability.
LLYdividendshareholder returns
The Motley FoolThe Motley Fool··Adria Cimino

Eli Lilly's Weight Loss Arsenal Accelerates: GLP-1 Portfolio Surges Past $12.7B

Eli Lilly's weight loss drugs deliver explosive growth with Mounjaro up 125% and Zepbound up 80%. New oral drug Foundayo already serves 20,000 patients.
PFELLYNVOVKTXmarket sharepharmaceutical growth
The Motley FoolThe Motley Fool··Reuben Gregg Brewer

Pfizer's 50% Decline Masks Hidden Opportunity in High-Yield Recovery Play

Pfizer's 50% stock decline masks a 6.4% dividend yield and strategic repositioning in GLP-1 drugs, oncology, and migraine treatments, offering potential upside for patient investors.
PFELLYbiotechdividend yield
GlobeNewswire Inc.GlobeNewswire Inc.··Jim Rickards

America's $9 Trillion Manufacturing Surge Ignites Mining and Energy Boom

U.S. corporations committed $9 trillion to domestic manufacturing, creating massive demand for critical minerals and energy. Federal government accelerates mining permits and invests directly in mineral producers to secure supply chains.
NVDALLYAAPLTSMMP+2supply chainmining
Investing.comInvesting.com··Nathan Reiff

Lilly's Double-Beat Widens GLP-1 Gap as Foundayo Pill Transforms Market

Eli Lilly beats Q1 earnings, raises $2B guidance, and wins FDA approval for Foundayo, the first unrestricted oral GLP-1, widening gap over Novo Nordisk.
LLYNVOFDA approvalweight loss medications
BenzingaBenzinga··Caroline Ryan

Sirius XM Eyes iHeartMedia Merger as M&A Wave Sweeps Across Sectors

Sirius XM explores iHeartMedia acquisition while Uber buys FlyTaxi and Sun Pharma completes $11.75B Organon deal. Multiple bankruptcies filed.
LLYUBERSIRIOGNIHRT+1acquisitionsM&A
BenzingaBenzinga··Rishabh Mishra

Stock Futures Rise as Trump Admin Sidesteps War Powers Deadline; Tech Earnings Mixed

Stock futures advanced Friday as mega-cap earnings beat expectations; Apple rose 3.11%, Twilio surged 20.69%, but Roblox fell 22.10% on guidance concerns.
SPYQQQLLYAAPLTEAM+2earningsstock market
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Nxera Pharma Posts Strong Q1 2026 as Spinoff Centessa Fetches $7.8B Lilly Deal

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.
ABBVLLYCNTANBIXrevenue growthdrug discovery
BenzingaBenzinga··Piero Cingari

Industrials Lift Wall Street as Tech Giants Stumble on AI Spending Concerns

Dow Jones surges 1.5% led by industrial stocks amid data-center demand, while mega-cap tech struggles with AI capital spending worries.
NVDAMETAMSFTAMZNGOOG+12earningssector rotation
BenzingaBenzinga··Vandana Singh

Eli Lilly Crushes Expectations, Raises 2026 Outlook on GLP-1 Dominance

Eli Lilly beat Q1 earnings expectations and raised full-year guidance, driven by blockbuster demand for weight-loss drugs Mounjaro and Zepbound.
LLYearningsacquisitions
The Motley FoolThe Motley Fool··Adria Cimino

CRISPR Therapeutics Eyes $223B Autoimmune Market With Gene-Editing Breakthrough

CRISPR Therapeutics leverages FDA-approved gene editing to target a $223B autoimmune disease market, positioning itself as the post-GLP-1 growth opportunity in biotech.
LLYVRTXNVOCRSPclinical trialsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Patentvest

Lilly's Retatrutide Hits Surgery-Level Weight Loss, But IP Wars Loom

Eli Lilly's retatrutide achieved 28.7% mean weight loss, matching bariatric surgery. However, competitive pressures from Novo Nordisk, Pfizer, and others are intensifying.
PFELLYSNYNVOintellectual propertyweight loss
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Morgan Stanley Sees 52% Upside for Eli Lilly as Weight-Loss Drugs Reshape Revenue

Morgan Stanley analyst targets $1,327 for Eli Lilly, citing $45B weight-loss drug sales potential by 2030, implying 52% upside from current $870 levels.
LLYCVSNVOweight loss drugsZepbound
GlobeNewswire Inc.GlobeNewswire Inc.··Delveinsight

RA Drug Pipeline Accelerates: 75+ Companies Race to Launch 80+ Therapies

DelveInsight's 2026 report shows robust rheumatoid arthritis pipeline with 75+ players developing 80+ drugs, featuring novel JAK and BTK inhibitors plus cell-based therapies.
BMYCELGrABBVLLYNVS+4clinical trialsdrug development